Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design.
about
Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumonPharmacogenomics of hypertension and heart diseaseWarfarin pharmacogenetics: does more accurate dosing benefit patients?Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing?A review of a priori regression models for warfarin maintenance dose prediction.Warfarin pharmacogenetics.Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.Clinically relevant genetic variations in drug metabolizing enzymes.The use of warfarin for DVT prophylaxis following hip and knee arthroplasty: how often are patients within their target INR range?Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin.Personalized medicine: is it a pharmacogenetic mirage?Myocardial ischaemia after hip and knee arthroplasty: incidence and risk factorsDevelopment of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patientsWarfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithmsPersonalized vascular medicine: individualizing drug therapyPharmacogenetic testing: Current Evidence of Clinical Utility.Pharmacogenetics in clinical pediatrics: challenges and strategies.Contrasting Medical and Legal Standards of Evidence: A Precision Medicine Case Study.A pharmacogenetic versus a clinical algorithm for warfarin dosing.Genetic determinants of response to cardiovascular drugs.Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.The future of inpatient anticoagulation management.Warfarin pharmacogenetics: to genotype or not to genotype, that is the question.Genotype-guided coumarin dosing: where are we now and where do we need to go next?Warfarin pharmacogenomics: current best evidence.Genetic testing to guide warfarin dosing: Impact of direct oral anticoagulants.Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.Genotyping of CYP2C9 and VKORC1 in the Arabic population of Al-Ahsa, Saudi Arabia.Use of signals and systems engineering to improve the safety of warfarin initiation.Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation.Combining genetic variations in CYP2C9 and VKORC1 with clinical factors for warfarin dosing determination improved clinical effectiveness.Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation.Time to revisit warfarin pharmacogenetics.Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.Genetic Testing in Clinical Settings.Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment.
P2860
Q26823542-27F950E1-5088-4776-B426-D54EC0A82B99Q27006860-8D488C4D-ABEC-48B6-BC9C-95EE6AFEBFABQ27015722-4412FB26-41A4-40FA-A8A3-9BCBE9CCA1EDQ27027304-F524BFDE-3BC7-4220-B4D2-E08F994305E5Q33946309-1364FF60-EB29-4D44-9FA6-3589A3745A10Q34690708-09536A57-9D82-441E-987C-77F1F7C0711AQ34785072-32964101-37DE-4DBA-8DDB-A23C5094F369Q34791041-EB07923A-B1E5-4E01-9B1C-8FF48BD53DD2Q35032378-C888F3EB-9268-4088-8A04-0D30BC28772BQ35071798-98D48392-574B-4C45-AE1D-C71E84E8CDB0Q36015458-DA73A4F9-6956-49A8-93A1-24031847A2F6Q36336007-77F0707C-F93B-4BF0-861F-999AEEB36B93Q36438801-89441B79-0F27-45C0-A814-3136C7EEBCF5Q36511894-3E9BDDB1-61FD-43FB-8EB2-B5407BFCFE4AQ36836979-E65D17BB-0569-46FA-93DD-6C3114E20C9EQ37142852-11B6BAF3-ED49-4B41-A061-544D8AFAC16DQ37151528-FEF60622-54CF-4881-AF46-49BF22AD1228Q37400384-DFC2C453-3FEC-46E4-8D75-6921E816958FQ37473370-19CF8BFC-7898-4F0A-A428-4580B4E97274Q37616712-FAA49B76-FA45-4B1C-97BA-9739551F50A8Q37989811-F65D598A-7C52-4C77-8100-B8F8E113186CQ38078754-8692E40F-D5C4-48BB-AD49-CCEA48DE9EA0Q38082467-857B77F0-A68F-46C6-9892-5BC4F5736560Q38221329-0FBC380B-9A9B-4B95-B614-F6D2FC061AFDQ38321269-F96C33C6-5333-4D88-AF2C-9D99BB4C8AA5Q38543302-0EB3B8D1-6570-47BF-AACB-5CF35EF16004Q38867357-08EF15B4-3D3D-4CE7-988F-E8EA49F65625Q38961083-207B1818-F452-47E4-B8EE-43BCF601617AQ39467511-202BA116-7BB9-4D4E-BD1C-DFB7FE293315Q39575603-8F5F5CD3-DCCC-41A1-94CA-EA727A3277E4Q44784933-0FE7A6B9-EEEE-482E-A84D-BF0211AD44E1Q45369313-6CBF032E-BDB1-4C32-A904-923527225784Q45974877-912C0D35-D540-4E1F-9FDA-B01839328CC9Q47920440-A2624F64-78E9-4AF1-AC40-CDC1D45AA7B8Q48580819-7BF28233-4105-4C83-9792-C8F477A2555EQ52588359-76270F92-4064-433C-AC8C-2047A4224985Q53088047-32CADEDA-B0EE-4177-8751-08A08D2A5D7F
P2860
Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Genetics informatics trial (GI ...... ): rationale and study design.
@ast
Genetics informatics trial (GI ...... ): rationale and study design.
@en
type
label
Genetics informatics trial (GI ...... ): rationale and study design.
@ast
Genetics informatics trial (GI ...... ): rationale and study design.
@en
prefLabel
Genetics informatics trial (GI ...... ): rationale and study design.
@ast
Genetics informatics trial (GI ...... ): rationale and study design.
@en
P2093
P2860
P356
P1476
Genetics informatics trial (GI ...... ): rationale and study design.
@en
P2093
G A McMillin
J L Anderson
R C Pendleton
R M Nunley
P2860
P2888
P304
P356
10.1038/TPJ.2011.18
P577
2011-05-24T00:00:00Z